Hospital da Luz Guimarães will conduct its first phase 3 clinical trial , designed for patients with chronic obstructive pulmonary disease (COPD) that experience frequent aggravation of symptoms. Throughout the trial – which will be conducted by pneumologist Maria José Guimarães , with the collaboration of other doctors and health professionals of the hospital and the support of Hospital da Luz Learning Health –, the experimental drug will be given to selected patients. Patients with COPD followed up at Hospital da Luz Guimarães and meeting the requirements to participate in this clinical trial will be identified and recruited by the clinical team. “The patients will be carefully selected and monitored along the process, thus ensuring that all ethical and safety rules are strictly followed ”, stresses Maria José Guimarães (in the photo above, with João Vieira da Silva, nurse specialist in rehabilitation). The clinical trials: Are the last stage of a drug’s development process, being a fundamental tool towards the advancement of science and the improvement of people’s health. In phase 3 clinical trials, the goal is to demonstrate, by comparison with the standard treatment, the efficacy, therapeutic advantage and safety of a new drug. Within Luz Saúde group, Hospital da Luz Learning Health is the structure that provides support to the clinical trials conducted in different units of Hospital da Luz network, coordinating their respective professional teams throughout such projects. For Hospital da Luz Guimarães, this is a significant step in the area of clinical research, beyond an accurate instrument to meet its commitment of innovation and excellence in healthcare.
